Lannett announced it has received FDA approval of its Abbreviated New Drug Application (ANDA) for Oxycodone HCl Capsules, the equivalent of Lehigh Valley Technologies Inc.’s listed reference Oxycodone HCl Capsules.
Oxycodone HCl is an opioid narcotic indicated for moderate to moderately severe pain. Oxycodone HCl is a pure agonist opioid that has multiple actions qualitatively similar to those of morphine. The most prominent of these involves the central nervous system and organs composed of smooth muscle.
Oxycodone HCl Capsules will be available in a 5mg strength. Lannett plans to ship the product in the coming months.
For more information call (215) 333-9000 or visit Lannett.com.